Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Engy A. Wahsh"'
Autor:
Engy A. Wahsh, Ahmed E. Abou Warda, Mahmoud S. Abdallah, Aya Elsayed, Yasser Soliman Abdel Daiem, Eman Mohamed Sadek
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Background Pharmacists have an important role in preventing prescribing errors and providing appropriate information. They can detect potential drug–drug interactions (DDIs), which are associated with a more extended hospital stay and high
Externí odkaz:
https://doaj.org/article/e8c432efbc0a4ccdb0daf0d439a881dc
Autor:
Sarya Swed, Hidar Alibrahim, Haidara Bohsas, Ahmed R. N. Ibrahim, Abdelmonem Siddiq, Nagham Jawish, Mark Hasib Makhoul, Maram Abdulmajid Mahmoud Alrezej, Fouad Hasib Makhoul, Bisher Sawaf, Wael Hafez, Sarah Makram Elsayed, Rami Soliman, Engy A. Wahsh
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: Proton pump inhibitors (PPIs) are commonly used to treat acid-related disorders. Their appropriate use depends on the correct indications from the clinician. Owing to the high incidence of use and misuse, PPIs have been identified as an
Externí odkaz:
https://doaj.org/article/19c1580f4bd846e88e3c34e553c9ee45
Publikováno v:
BMC Nephrology, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background The prevalence of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) is increasing continuously as a result of the dramatic growth in the prevalence of two main causes of ESKD which are diabetes mellitus (DM) and hyp
Externí odkaz:
https://doaj.org/article/8e9a22503f8f4eb3a66c7561f745d1c5
The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
Autor:
Sahar H. Elhini, Engy A. Wahsh, Ahmed A. Elberry, Nadia F. El Ameen, Ahmed Abdelfadil Saedii, Shereen Mahmoud Refaie, Asmaa A. Elsayed, Hoda M. Rabea
Publikováno v:
Pharmaceuticals, Vol 15, Iss 12, p 1516 (2022)
Non-alcoholic fatty liver disease (NAFLD) is related to metabolic syndrome via insulin resistance, where preventing disease progression is crucial in the management process. The study included 240 NAFLD patients with type 2 diabetes who were randomly
Externí odkaz:
https://doaj.org/article/90d555a1b53541d288ebe14edb6e53d4
Publikováno v:
Medicine Science, Vol 7, Iss 1, Pp 122-126 (2018)
Chronic infection with HCV is a worldwide health problem that may lead to cirrhosis, portal hypertension, hepatocellular failure and hepatocellular carcinoma in most of cases. A new era in HCV treatment has been started using direct acting antiviral
Externí odkaz:
https://doaj.org/article/7f0e991305d544c1863e1ef88d6d4d39
Autor:
Karam R. Motawea, Hamed Gaber, Ravi B. Singh, Sarya Swed, Salem Elshenawy, Nesreen Elsayed Talat, Nawal Elgabrty, Sheikh Shoib, Engy A. Wahsh, Pensée Chébl, Sarraa M. Reyad, Samah S. Rozan, Hani Aiash
Publikováno v:
Clinical Cardiology. 45:1011-1028
This meta-analysis aims to look at the impact of early intravenous Metoprolol in ST-segment elevation myocardial infarction (STEMI) before percutaneous coronary intervention (PCI) on infarct size, as measured by cardio magnetic resonance (CMR) and le
Publikováno v:
Current Medical Science. 41:581-586
Hepatitis C virus genotype 4 (HCV-GT4) is a risk factor for cirrhosis, hepatocellular carcinoma and liver failure. A combination of three new direct-acting antivirals ombitasvir, paritaprevir, and ritonavir has been recommended for treatment of HCV-G
Publikováno v:
Infectious Disorders - Drug Targets. 20:43-48
Background: Chronic infection with Hepatitis C virus (HCV) is considered as a major cause for developing liver cirrhosis and hepatocellular carcinoma. A new era in HCV treatment is ongoing using Direct Acting Antiviral activity (DAA). The first appro
Autor:
Engy A. Wahsh, Sayed Ahmed, Essam Hassan, Ahmed Gomaa, Gamal Esamat, Ahmed Ramadan, Manar Ahmed, Aya Elsayed
Publikováno v:
Current drug safety.
Background: Chronic infection with HCV is progressive worldwide health problem and the core reason for liver cirrhosis, portal hypertension, or hepatocellular carcinoma. HCV-G4 represents the most common threat to transplantation of the liver in Egyp
Autor:
Sarya Swed, Karam R Motawea, Yossef Hassan AbdelQadir, Mohamed Gamal, Amro A El-Sakka, Omneya A Kandil, Basel Abdelazeem, Muhammad Abdelaziz, Engy A Wahsh
Publikováno v:
Journal of Clinical Oncology. 40:e16147-e16147
e16147 Background: Recent studies have assessed the efficacy of some therapeutics in advanced hepatocellular carcinoma. Our aim is to perform a meta-analysis to compare the efficacy of Camrelizumab and Apatinib combination therapy versus Apatinib onl